These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 29039073

  • 21. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
    Navari RM, Gray SE, Kerr AC.
    J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
    [Abstract] [Full Text] [Related]

  • 22. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [Abstract] [Full Text] [Related]

  • 23. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 24. Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
    Ishido K, Higuchi K, Azuma M, Sasaki T, Tanabe S, Katada C, Yano T, Wada T, Koizumi W, Kitasato Digestive Disease & Oncology Group.
    Anticancer Drugs; 2016 Oct 01; 27(9):884-90. PubMed ID: 27254283
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 32. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
    Wang SY, Yang ZJ, Zhang L.
    Asian Pac J Cancer Prev; 2014 Jun 15; 15(22):9587-92. PubMed ID: 25520071
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial.
    Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, Srinivas S, Kapoor A, Mishra BK, Gupta A, Sansar B, Pal V, Pandey A, Bonda A, Siripurapu I, Muddu VK, Kannan S, Chaugule D, Patil R, Parulekar M, Dhanawat A, Trikha M, Ghosh J, Noronha V, Menon N, Patil V, Prabhash K, Olver I.
    JAMA Netw Open; 2024 Aug 01; 7(8):e2426076. PubMed ID: 39106066
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, Yamakage M.
    J Pain Symptom Manage; 2014 Mar 01; 47(3):542-50. PubMed ID: 23856100
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.
    Wang W, Lou G, Zhang Y.
    Medicine (Baltimore); 2018 Sep 01; 97(37):e12331. PubMed ID: 30212982
    [Abstract] [Full Text] [Related]

  • 40. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Herrington JD, Jaskiewicz AD, Song J.
    Cancer; 2008 May 01; 112(9):2080-7. PubMed ID: 18327813
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.